Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)